Cargando…

Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice

BACKGROUND: Non-adherence is a major obstacle with long-term daily statin therapy. OBJECTIVE: This retrospective study reviewed the medical records of patients with hyperlipidemia during an 8-year period in a private internal medicine practice. Periodic dosing was negotiated following several patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Christou, Theodore, Omar, Hesham R., Dimitrov, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269817/
https://www.ncbi.nlm.nih.gov/pubmed/25160776
http://dx.doi.org/10.1007/s40268-014-0061-9
_version_ 1782349394752831488
author Christou, Theodore
Omar, Hesham R.
Dimitrov, Roger
author_facet Christou, Theodore
Omar, Hesham R.
Dimitrov, Roger
author_sort Christou, Theodore
collection PubMed
description BACKGROUND: Non-adherence is a major obstacle with long-term daily statin therapy. OBJECTIVE: This retrospective study reviewed the medical records of patients with hyperlipidemia during an 8-year period in a private internal medicine practice. Periodic dosing was negotiated following several patients’ refusal of statin therapy because of muscle aches or cost. METHODS: The clinical impetus was patient adherence to statin therapy. Treatment was initiated by dispensing rosuvastatin or atorvastatin in a stepwise patient-directed approach (from two times/week to three times/week to every other day, up to five times/week). The primary endpoint was to assess the concentration of low-density lipoprotein cholesterol (LDL-C) and the total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratio with patient-directed dosing intervals. The secondary endpoint was a head-to-head comparison of atorvastatin and rosuvastatin to evaluate the mean decrease in the LDL-C and TC/HDL-C ratio. RESULTS: Chart review identified 46 patients who had been treated. Two patients with persistent myalgia terminated treatment before 12 weeks. Among the remaining 44 patients, 20 received doses of rosuvastatin from 15 to 100 mg per week, and 24 received atorvastatin from 20 to 140 mg per week. There was a significant decrease from pre-treatment in the mean TC/HDL-C ratio of 1.72 (31.1 %, P < 0.0001) and mean LDL-C of 43.3 mg/dL (30.2 %, P < 0.0001). An independent samples t-test showed a non-significant reduction of the mean TC/HDL-C ratio and LDL-C with rosuvastatin versus atorvastatin. CONCLUSION: Periodic dosing of rosuvastatin or atorvastatin using a gradual, patient-directed, stepwise approach guided by cholesterol levels is an effective method of lipid lowering and carried a favorable 95.6 % adherence rate.
format Online
Article
Text
id pubmed-4269817
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-42698172014-12-22 Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice Christou, Theodore Omar, Hesham R. Dimitrov, Roger Drugs R D Original Research Article BACKGROUND: Non-adherence is a major obstacle with long-term daily statin therapy. OBJECTIVE: This retrospective study reviewed the medical records of patients with hyperlipidemia during an 8-year period in a private internal medicine practice. Periodic dosing was negotiated following several patients’ refusal of statin therapy because of muscle aches or cost. METHODS: The clinical impetus was patient adherence to statin therapy. Treatment was initiated by dispensing rosuvastatin or atorvastatin in a stepwise patient-directed approach (from two times/week to three times/week to every other day, up to five times/week). The primary endpoint was to assess the concentration of low-density lipoprotein cholesterol (LDL-C) and the total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratio with patient-directed dosing intervals. The secondary endpoint was a head-to-head comparison of atorvastatin and rosuvastatin to evaluate the mean decrease in the LDL-C and TC/HDL-C ratio. RESULTS: Chart review identified 46 patients who had been treated. Two patients with persistent myalgia terminated treatment before 12 weeks. Among the remaining 44 patients, 20 received doses of rosuvastatin from 15 to 100 mg per week, and 24 received atorvastatin from 20 to 140 mg per week. There was a significant decrease from pre-treatment in the mean TC/HDL-C ratio of 1.72 (31.1 %, P < 0.0001) and mean LDL-C of 43.3 mg/dL (30.2 %, P < 0.0001). An independent samples t-test showed a non-significant reduction of the mean TC/HDL-C ratio and LDL-C with rosuvastatin versus atorvastatin. CONCLUSION: Periodic dosing of rosuvastatin or atorvastatin using a gradual, patient-directed, stepwise approach guided by cholesterol levels is an effective method of lipid lowering and carried a favorable 95.6 % adherence rate. Springer International Publishing 2014-08-27 2014-12 /pmc/articles/PMC4269817/ /pubmed/25160776 http://dx.doi.org/10.1007/s40268-014-0061-9 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research Article
Christou, Theodore
Omar, Hesham R.
Dimitrov, Roger
Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
title Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
title_full Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
title_fullStr Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
title_full_unstemmed Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
title_short Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
title_sort periodic rosuvastatin or atorvastatin dosing arrays (prada): patient-centered practice
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269817/
https://www.ncbi.nlm.nih.gov/pubmed/25160776
http://dx.doi.org/10.1007/s40268-014-0061-9
work_keys_str_mv AT christoutheodore periodicrosuvastatinoratorvastatindosingarrayspradapatientcenteredpractice
AT omarheshamr periodicrosuvastatinoratorvastatindosingarrayspradapatientcenteredpractice
AT dimitrovroger periodicrosuvastatinoratorvastatindosingarrayspradapatientcenteredpractice